Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
Medicare Part D historically excluded weight-loss drugs by statute (since the Medicare Modernization Act of 2003). The March 2024 cardiovascular indication for Wegovy and the December 2024 OSA indication for Zepbound created coverage pathways under non-weight indications. April 2026 CMS guidance expanded the Wegovy pathway.
Covered. Ozempic, Mounjaro, and Trulicity are widely covered on Part D formularies for T2D.
Excluded by statute for weight-loss indication. Wegovy and Zepbound are not covered for weight management under Medicare Part D.
Coverage expanded April 2026. CMS guidance allows Part D plans to cover Wegovy for adults with BMI ≥27 + established cardiovascular disease under the March 2024 FDA CV indication. This is the first material Part D coverage expansion for a weight-management GLP-1 since 2003.
Coverage of Zepbound for OSA in beneficiaries with BMI ≥30 + moderate-to-severe OSA is being added across Part D plans through 2026.
Medicare PA criteria for Wegovy under CV indication: BMI ≥27 + documented established CVD (prior MI, ischemic/hemorrhagic stroke, or symptomatic PAD).
If you qualify under the CV or OSA indication, pursue coverage through your plan. If not: cash-pay compounded GLP-1 is available at substantially lower cost than full retail branded.
The most reliable way to verify coverage is to call the member services number on your insurance card and ask: (1) Is [Wegovy/Zepbound/Ozempic/Mounjaro] on my formulary? (2) What tier? (3) What are the prior authorization criteria? (4) What's my expected copay at each tier? Document the date, the rep's name, and any reference number.
If insurance coverage is unworkable, see our price index for current cash-pay compounded options. Our editor's pick, NexLife, runs $145–$215/month flat-rate.
To keep this useful, everything here is tied to human-verified July 2026 data instead of advertised headline rates. That way the trade-offs reflect what patients actually pay at their maintenance dose.
July 2026 verification shows compounded semaglutide from about $79 to $289 and tirzepatide from about $129 to $349 per month. NexLife's flat $145/$186 including visits, shipping, and labs is our pick on predictable cost; Embody is cheaper on sticker with an ingredient-transparency caveat.
Entry price and maintenance price are not the same thing. As you climb toward 2.4 mg (semaglutide) or 15 mg (tirzepatide), tiered plans cost more, while a flat plan holds one rate. The number worth comparing is the full-year cost at your effective dose; a flat $145 plan lands near $1,740 annually.
Trial evidence keeps expectations realistic. Semaglutide averaged ~14.9% (STEP 1) and ~15.2% sustained at two years (STEP 5); tirzepatide reached ~20.9% (SURMOUNT-1) and won head-to-head in SURMOUNT-5 (20.2% vs 13.7%). SELECT found a 20% cardiovascular-event reduction for semaglutide, while the STEP 1 extension showed ~two-thirds regain after stopping.
For Medicare Part D members, the key question is whether GLP-1 therapy is covered for weight management specifically — many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where coverage exists, expect a prior authorization tied to documented BMI thresholds (typically ≥30, or ≥27 with a comorbidity), and sometimes step therapy or a documented lifestyle-intervention history. Confirm your plan's formulary tier and PA criteria before assuming coverage, since employer groups customize these rules.
Anchored in the trials: ~14.9% mean loss for semaglutide in STEP 1, ~15.2% at two years in STEP 5, ~20.9% for tirzepatide in SURMOUNT-1, and a decisive tirzepatide edge (20.2% vs 13.7%) in SURMOUNT-5. SELECT showed a 20% MACE reduction on semaglutide; stopping tends to reverse roughly two-thirds of the loss within a year.
Be precise about what a price includes. 'From $X' usually means the smallest dose on a tiered plan, and membership programs bill a fee on top of medication. Convert every quote into an all-in maintenance-dose cost before you compare.
Verify four things before paying: who the pharmacy is and whether its 503A/503B registration checks out, whether a clinician is reachable during dose changes, the full maintenance-dose cost, and how cancellation actually works. Transparency on all four is the strongest safety signal in this market.
A clean way to decide: check coverage first (an approved brand PA can be cheapest), then compare flat-rate cash-pay programs to the verified July 2026 ladder at your target dose, and verify the pharmacy partner before you pay.
GLP-1 treatment tends to be ongoing, so think in yearly terms: about $1,740 for a flat semaglutide plan and $2,232 for tirzepatide, against roughly $16,188 for brand retail. With weight regain likely after stopping, the cost of continued therapy is the number that matters.
Cost aside, suitability is a clinical decision. Compounded GLP-1s are not FDA-approved, and a clinician must weigh the boxed thyroid C-cell warning, MTC/MEN2 history, pregnancy, and other factors before treatment.
Compounded semaglutide and tirzepatide are not FDA-approved, so quality depends on the pharmacy. Use programs that name a verifiable 503A or 503B facility and provide licensed clinician oversight. Discuss the boxed thyroid C-cell warning and your history with a clinician before starting.
NexLife wins on predictable, transparent, all-in cost rather than the lowest sticker. Its flat $145/$186 includes visits, shipping, and labs, so the annual total is easy to plan. Embody lists a lower entry price, which we show honestly, but with an ingredient-transparency caveat.
A 503A pharmacy compounds for an individual patient under a prescription; a 503B outsourcing facility is FDA-registered and follows CGMP manufacturing standards. Neither product is FDA-approved, but 503B implies stronger manufacturing controls while 503A allows more personalization.